Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR).

[1]  S. Arnold,et al.  Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities , 2018, Diabetes.

[2]  Charles E. Leonard,et al.  Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study , 2018, Pharmacoepidemiology and drug safety.

[3]  M. Boemi,et al.  Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. , 2017, The lancet. Diabetes & endocrinology.

[4]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[5]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study , 2017 .

[6]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.

[7]  8. Pharmacologic Approaches to Glycemic Treatment , 2016, Diabetes Care.

[8]  David W. Johnson,et al.  Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.

[9]  N. Wong,et al.  Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry , 2016, Diabetes Care.

[10]  S. Hutfless,et al.  Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes , 2016, Annals of Internal Medicine.

[11]  J. Gross,et al.  The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials , 2016, PLoS medicine.

[12]  S. Hutfless,et al.  Diabetes Medications for Adults With Type 2 Diabetes: An Update , 2016 .

[13]  D. Tanné,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[14]  A. Shillington,et al.  Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict , 2015, BMC Health Services Research.

[15]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[16]  J. Spertus,et al.  Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. , 2015, American heart journal.

[17]  B. Vandermeer,et al.  Mortality risk among sulfonylureas: a systematic review and network meta-analysis. , 2015, The lancet. Diabetes & endocrinology.

[18]  F. Hu,et al.  Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women , 2014, Diabetes Care.

[19]  F. Haaijer-Ruskamp,et al.  Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial , 2014, BMJ : British Medical Journal.

[20]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[21]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[22]  A. Vaag,et al.  Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.

[23]  B. Wells,et al.  The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy , 2010, Diabetes Care.

[24]  Gordon H Guyatt,et al.  The diabetes mellitus medication choice decision aid: a randomized trial. , 2009, Archives of internal medicine.

[25]  B. Zinman,et al.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy , 2008, Diabetologia.

[26]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[27]  Sander Greenland,et al.  Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. , 2004, American journal of epidemiology.

[28]  G. Zou,et al.  A modified poisson regression approach to prospective studies with binary data. , 2004, American journal of epidemiology.